Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas... Show more
CRIS is expected to report earnings to fall 43.03% to -228 cents per share on November 05
Q3'26
Est.
$-2.29
Q2'26
Beat
by $4.23
Q1'26
Missed
by $14.40
Q4'25
Beat
by $2.00
Q3'25
Beat
by $0.82
The last earnings report on July 30 showed earnings per share of -401 cents, beating the estimate of -825 cents. With 41.03K shares outstanding, the current market capitalization sits at 936.81K.